Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jongwan Chu"'
Autor:
Chan Gyu Lee, TaeEun Kim, Sungyoul Hong, Jongwan Chu, Ju Eun Kang, Hee Geon Park, Jun Young Choi, Kyoung Song, Sun Young Rha, Soohyeon Lee, Joon-Seok Choi, Sun Min Kim, Hae Min Jeong, Young Kee Shin
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Type I interferon (IFN) has been approved as an anticancer agent to treat some malignancies. However, IFNs have a short in vivo half-life, systemic toxicity, and poor biophysical properties, which prevent it from being widely used for cancer therapy.
Externí odkaz:
https://doaj.org/article/6c9e811c8b6e4038a696676a57153737
Autor:
Chan Gyu Lee, TaeEun Kim, Sungyoul Hong, Jongwan Chu, Ju Eun Kang, Hee Geon Park, Jun Young Choi, Kyoung Song, Sun Young Rha, Soohyeon Lee, Joon-Seok Choi, Sun Min Kim, Hae Min Jeong, Young Kee Shin
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2021)
Frontiers in Pharmacology, Vol 11 (2021)
Type I interferon (IFN) has been approved as an anticancer agent to treat some malignancies. However, IFNs have a short in vivo half-life, systemic toxicity, and poor biophysical properties, which prevent it from being widely used for cancer therapy.
Autor:
Tae-Eun Kim, Chan Gyu Lee, Jongwan Chu, Sungyoul Hong, Ju Eun Kang, Young Kee Shin, Hae Min Jeong
Publikováno v:
Cancer Research. 81:LB170-LB170
Background: Interferon beta (IFN-β), a promising potent cytokine, has been attracting attention for treatment of cancer. The pleiotropic antitumor effects of IFN-β have been studied, with specific reference to their direct role on cancer cells and